Class information for:
Level 1: ABATACEPT//TOCILIZUMAB//DISEASE MODIFYING ANTIRHEUMATIC DRUGS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
252 3731 38.5 83%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
389 16325 RHEUMATOID ARTHRITIS//RHEUMATOLOGY//RHEUMATOL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ABATACEPT Author keyword 91 53% 3% 120
2 TOCILIZUMAB Author keyword 42 29% 3% 123
3 DISEASE MODIFYING ANTIRHEUMATIC DRUGS Author keyword 41 41% 2% 79
4 EARLY RHEUMATOID ARTHRITIS Author keyword 41 36% 2% 91
5 DMARDS Author keyword 36 40% 2% 70
6 EARLY ARTHRITIS Author keyword 31 45% 1% 53
7 ETANERCEPT Author keyword 30 15% 5% 191
8 DAS28 Author keyword 26 51% 1% 37
9 GOLIMUMAB Author keyword 24 43% 1% 42
10 DISEASE ACTIVITY SCORE Author keyword 22 42% 1% 41

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ABATACEPT 91 53% 3% 120 Search ABATACEPT Search ABATACEPT
2 TOCILIZUMAB 42 29% 3% 123 Search TOCILIZUMAB Search TOCILIZUMAB
3 DISEASE MODIFYING ANTIRHEUMATIC DRUGS 41 41% 2% 79 Search DISEASE+MODIFYING+ANTIRHEUMATIC+DRUGS Search DISEASE+MODIFYING+ANTIRHEUMATIC+DRUGS
4 EARLY RHEUMATOID ARTHRITIS 41 36% 2% 91 Search EARLY+RHEUMATOID+ARTHRITIS Search EARLY+RHEUMATOID+ARTHRITIS
5 DMARDS 36 40% 2% 70 Search DMARDS Search DMARDS
6 EARLY ARTHRITIS 31 45% 1% 53 Search EARLY+ARTHRITIS Search EARLY+ARTHRITIS
7 ETANERCEPT 30 15% 5% 191 Search ETANERCEPT Search ETANERCEPT
8 DAS28 26 51% 1% 37 Search DAS28 Search DAS28
9 GOLIMUMAB 24 43% 1% 42 Search GOLIMUMAB Search GOLIMUMAB
10 DISEASE ACTIVITY SCORE 22 42% 1% 41 Search DISEASE+ACTIVITY+SCORE Search DISEASE+ACTIVITY+SCORE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MODIFYING ANTIRHEUMATIC DRUGS 493 52% 18% 680
2 RECEIVING CONCOMITANT METHOTREXATE 193 69% 4% 163
3 PLUS METHOTREXATE 192 70% 4% 159
4 INADEQUATE RESPONSE 188 56% 6% 232
5 ANTITUMOR NECROSIS FACTOR 175 40% 9% 345
6 COLLEGE OF RHEUMATOLOGY 134 52% 5% 184
7 CONCOMITANT METHOTREXATE 132 57% 4% 154
8 INTERLEUKIN 6 RECEPTOR INHIBITION 123 69% 3% 105
9 ADALIMUMAB PLUS METHOTREXATE 114 74% 2% 84
10 ALPHA MONOCLONAL ANTIBODY 112 42% 5% 202

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MODERN RHEUMATOLOGY 13 11% 3% 112

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update 2014 178 125 71%
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs 2010 616 106 78%
Treating rheumatoid arthritis to target: recommendations of an international task force 2010 523 64 67%
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges 2015 5 132 64%
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis 2012 70 61 92%
What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review 2014 17 39 79%
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials 2006 1151 54 37%
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis 2012 72 104 80%
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA 2010 178 73 86%
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis 2008 592 213 35%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DANBIO 21 90% 0.2% 9
2 G PINI ORTHOPED 13 80% 0.2% 8
3 METROPLEX CLIN 13 71% 0.3% 10
4 NIHR LEEDS MUSCULOSKELETAL BIOMED UNIT 12 23% 1.3% 47
5 UNIT CLIN THER Y 12 54% 0.4% 15
6 LOSSPK KLIN 10 43% 0.5% 18
7 RHEUMATOL IMMUNOL UNIT 10 58% 0.3% 11
8 SERV POLE RHUMATOL 9 83% 0.1% 5
9 ORTHOPED SURG RHEUMATOL 8 45% 0.4% 14
10 CLINTRID 8 100% 0.1% 5

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000259615 AG LES MARKUS KRANKENHAUS//DESERT ORTHOPED//DISEASE MODIFYING ANTI RHEUMATIC DRUGS DMARD
2 0.0000212820 WORK DISABILITY//WORK INSTABILITY//CARDIOVASC DIS SPECIAL MED
3 0.0000209506 JOINT SPACE MEASUREMENT//COMPUTER AIDED JOINT SPACE ANALYSIS//SHARP SCORE
4 0.0000194971 ANTI TNF ALPHA THERAPIES//GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID//PATHOL RHEUMATOL
5 0.0000190019 AIMS2//HEALTH ASSESSMENT QUESTIONNAIRE//MDHAQ
6 0.0000133151 DRUG INDUCED LUPUS//DRUG INDUCED LUPUS ERYTHEMATOSUS//TNF ALPHA ANTAGONISTS
7 0.0000122673 RHEUMATOLOTA KU//MDR I//DANINI HOSP
8 0.0000122409 METHOTREXATE//METHOTREXATE POLYGLUTAMATES//MX 68
9 0.0000110587 COPCORD//RHEUMATIC MUSCULOSKELETAL DISORDERS//COMMUNITY BASED EPIDEMIOL PREVENT TREATMENT RHE
10 0.0000108474 SYNOVITIS//CLIN REUMATOL//ENTHESITIS